<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05106972</url>
  </required_header>
  <id_info>
    <org_study_id>SCT20181032</org_study_id>
    <nct_id>NCT05106972</nct_id>
  </id_info>
  <brief_title>Umbilical Cord Mesenchymal Stem Cell Transplantation for Decompensated Hepatitis B Cirrhosis</brief_title>
  <official_title>A Single Center, Prospective Study of Umbilical Cord Mesenchymal Stem Cell Transplantation for Decompensated Hepatitis B Cirrhosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asia Stem Cell Regenerative Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asia Stem Cell Regenerative Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the safety and clinical efficacy of umbilical cord mesenchymal&#xD;
      stem cell transplantation for decompensated hepatitis B cirrhosis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with abnormal Total bilirubin</measure>
    <time_frame>Changes from baseline to 72 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with abnormal albumin</measure>
    <time_frame>Changes from baseline to 72 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Ishak Inflammation Rating System</measure>
    <time_frame>Changes from baseline to 72 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Ishak Fibrosis Score</measure>
    <time_frame>Changes from baseline to 72 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Changes from baseline to 72 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBV-DNA</measure>
    <time_frame>Changes from baseline to 72 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of liver cancer</measure>
    <time_frame>Changes from baseline to 72 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with abnormal immunoglobulin</measure>
    <time_frame>Changes from baseline to 72 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>portal vein flow rate</measure>
    <time_frame>Changes from baseline to 72 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>portal vein width</measure>
    <time_frame>Changes from baseline to 72 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>abdominal volume</measure>
    <time_frame>Changes from baseline to 72 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with abnormal coagulation function</measure>
    <time_frame>Changes from baseline to 72 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Liver Cirrhosis</condition>
  <arm_group>
    <arm_group_label>UC-MSC infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>UC-MSC infusion by intravenus, 1*10^8 cells/dose, 2 doses (apart from 24weeks)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>UC-MSC infusion</intervention_name>
    <description>UC-MSC infusion by introvenus</description>
    <arm_group_label>UC-MSC infusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged between 20 and 60 (male or female)&#xD;
&#xD;
          -  Diagnosed chronic decompensated hepatitis B cirrhosis with a course of more than 5&#xD;
             years&#xD;
&#xD;
          -  Not suitable for liver transplantation or there is no donor liver source&#xD;
&#xD;
          -  No serious bleeding tendency or active bleeding&#xD;
&#xD;
          -  No hepatic encephalopathy&#xD;
&#xD;
          -  After strict medical conservative treatment for more than 6 months, there was no&#xD;
             relief of symptoms or significant improvement of quality of life score&#xD;
&#xD;
          -  Subjects voluntarily participate in this study and sign informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Be less than 20 years old or more than 60 years old&#xD;
&#xD;
          -  Cirrhosis caused by other causes such as alcoholic hepatitis, hepatitis C virus and&#xD;
             autoimmune hepatitis&#xD;
&#xD;
          -  Found liver malignant tumor or the family history of liver malignant tumor in the&#xD;
             third generation of their direct relatives&#xD;
&#xD;
          -  Patients with hypersplenism who need splenectomy&#xD;
&#xD;
          -  History of tumors in other organs&#xD;
&#xD;
          -  PT prolongation is greater than 3 seconds&#xD;
&#xD;
          -  Use of human serum albumin within 3 weeks prior to clinical registration&#xD;
&#xD;
          -  Clinically significant upper gastrointestinal bleeding events occurred within 4 weeks&#xD;
             before clinical registration&#xD;
&#xD;
          -  Spontaneous peritonitis&#xD;
&#xD;
          -  Active infection (viral or bacterial)&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  The researcher considers it inappropriate to participate in this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xiaoxi Huang, PHD</last_name>
    <phone>86-0898-66151200</phone>
    <email>huangxiaoxi@xibaozhiliao.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Haikou People's Hospital</name>
      <address>
        <city>Haikou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaoxi Huang, PHD</last_name>
      <phone>86-0898-66151200</phone>
      <email>huangxiaoxi@xibaozhiliao.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 19, 2021</study_first_submitted>
  <study_first_submitted_qc>October 31, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 4, 2021</study_first_posted>
  <last_update_submitted>October 31, 2021</last_update_submitted>
  <last_update_submitted_qc>October 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

